CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERAâ.,¢ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The positive opinion is now referred to the European Commission (EC) for an. ...

Company Overview - Haemonetics Corporation provides blood management solutions globally, serving blood and plasma collectors, hospitals, and healthcare providers. The company's offerings include integrated devices, information management, and consulting services that enhance clinical outcomes across the blood supply chain [11]. Investment Insights - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12]. - The stock has a Momentum Style Score of B, with shares increasing by 50.5% over the past four weeks, suggesting strong recent performance [12]. - For fiscal 2026, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising by $0.07 to $4.87 per share. The company has an average earnings surprise of +6% [12]. Conclusion - With a strong Zacks Rank and favorable Momentum and VGM Style Scores, Haemonetics is positioned as a noteworthy option for investors [13].

Core Insights - SG Capital Management LLC reduced its holding in Haemonetics Corporation by 731,892 shares, resulting in a position value decline of approximately $59.1 million as of November 7, 2025 [1][2]. Company Overview - Haemonetics Corporation is a leading provider of medical devices and software for blood and plasma management, addressing critical needs in transfusion medicine and plasma collection through a diversified product portfolio and integrated technology platforms [5][6]. - The company generates revenue primarily from the sale of medical devices, disposables, and integrated software solutions to healthcare providers and plasma collection centers globally [6]. Financial Performance - For the trailing twelve months (TTM), Haemonetics reported revenue of $1.33 billion and net income of $168.19 million [4]. - The company's share price as of November 6, 2025, was $67.11, reflecting a 14.14% decline over the past year, underperforming the S&P 500 by 27.5 percentage points [4][10]. Recent Developments - Haemonetics reported a 5% decline in revenue for the fiscal second quarter, totaling $327 million, with a 1.8% drop when excluding foreign-currency exchange impacts and divestitures [8]. - Management's guidance for the full year's adjusted revenue indicates a potential decline of 1% to an increase of 2%, which is an improvement from previous guidance [9]. Investment Activity - Following the reduction in its stake, Haemonetics now accounts for only 0.8% of SG Capital's total 13F assets under management (AUM), down from 4.7% in the prior quarter [10]. - The market reacted positively to Haemonetics' results and guidance, with the share price increasing by 35% in the two days following the earnings release [11].

Core Insights - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] Group 1 - The analysis occasionally includes large-cap companies to provide a broader perspective on the equity markets [1]

Group 1 - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] - Occasionally, large-cap companies are analyzed to provide a broader perspective on the equity markets [1] Group 2 - There is a beneficial long position in the shares of HAE, indicating a positive outlook on the company's stock [2]

Core Insights - Haemonetics reported Q3 CY2025 revenue of $327.3 million, a 5.3% decline year-on-year, but exceeded analyst estimates of $310.8 million [1][6] - The company achieved a non-GAAP profit of $1.27 per share, which was 14.3% above analysts' consensus estimates of $1.11 [1][6] - Adjusted EBITDA was $112.2 million, representing a 34.3% margin and a 14% beat against analyst expectations [6] Management Commentary - Management attributed the revenue outperformance to strong share gains in plasma collection solutions and sustained growth in Blood Management Technologies, alongside disciplined cost management [3][5] - CEO Chris Simon highlighted the results as a reflection of disciplined execution, strong core product growth, record margin expansion, and solid cash-converting earnings [3] - The hospital segment contributed significantly to operating margin improvement, driven by demand for viscoelastic testing and actions to address underperformance in interventional technologies [3] Future Outlook - Haemonetics updated its guidance, focusing on plasma share gains, new product launches, and continued cost discipline [4] - The company is rolling out its heparinase neutralization cartridge in Europe and Japan, with targeted investments to boost interventional technology growth, particularly in vascular closure [4] - Planned acquisition of Vivasure and further product pipeline expansion are seen as potential growth drivers beyond the current year [4] Financial Metrics - Operating margin improved to 17.9%, up from 15% in the same quarter last year [6] - Organic revenue fell by 1.8% year-on-year, outperforming analyst estimates of a 5.3% decline [6] - Market capitalization stands at $3.23 billion [6]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Haemonetics shares surged 22.1% following the release of third-quarter results that exceeded analyst expectations and an upward revision of full-year financial guidance [1][2] Financial Performance - The company reported adjusted earnings of $1.27 per share on revenue of $327.3 million, both surpassing Wall Street forecasts [2] - Total revenue declined 5.3% year-on-year, but organic revenue fell only 1.8%, indicating resilience in core operations [2] - Operating margin improved to 17.9% from 15% in the same quarter last year, and free cash flow reached $106.3 million [2] - Management raised full-year adjusted earnings per share guidance to a midpoint of $4.90 [2] Market Reaction - Haemonetics shares are characterized by low volatility, with only 8 moves greater than 5% in the past year, suggesting significant market impact from recent news [4] - The stock has experienced a decline of 16.9% since the beginning of the year and is currently trading 30.2% below its 52-week high of $93.38 [6]

Financial Data and Key Metrics Changes - Second quarter revenue was $327 million, reflecting a 5% reported revenue decline, while year-to-date revenue was $649 million, also down 5% [4] - Adjusted EPS increased 13% in the quarter to $1.27 and 11% year-to-date to $2.36 [16] - Adjusted gross margin reached 60.5% in the second quarter, up 380 basis points year-over-year [12] - Adjusted operating income increased 5% in the second quarter to $87 million, with adjusted operating margin expanding 250 basis points to 26.7% [15] Business Line Data and Key Metrics Changes - Hospital revenue was $146 million in the second quarter, up 5% on a reported basis and 4% organic [5] - Blood management technologies grew 12% in the quarter and 13% year-to-date, driven by hemostasis management [5] - Plasma revenue was $125 million in the quarter, down 10% on a reported basis, but organic revenue grew 19% [8] - Blood center reported revenue declined 18% in the quarter, but organic revenue grew 4% [10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the high single digits, while European collections continued to grow in double digits [9] - The company raised its full-year plasma revenue guidance to a decline of 4%-7% or 14%-17% organic growth excluding CSL [9] - Hospital revenue growth guidance was updated to 4%-7%, reflecting sustained growth in blood management technologies [8] Company Strategy and Development Direction - The company is focused on advancing its portfolio and transformation to sustain momentum beyond its long-range plan [4] - Strategic priorities include meeting debt obligations, returning excess cash to shareholders, and advancing targeted investments in growth products [20] - The company aims to strengthen execution in interventional technologies to accelerate growth and margin expansion beyond FY 2026 [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustained robust growth of the plasma therapeutics market, particularly immunoglobulins [9] - The company anticipates continued margin expansion in the second half of the fiscal year [16] - Management highlighted the importance of disciplined execution and a high-performance culture in driving long-term value creation [20] Other Important Information - The company raised its full-year revenue guidance from a reported decline of 3%-6% to a decline of 1%-4% [11] - Free cash flow guidance was raised to $170-$210 million, with a commitment to maintain a free cash flow to adjusted net income ratio in excess of 70% [18] - The company ended the quarter with $296 million in cash and total debt of $1.2 billion [18] Q&A Session Summary Question: What are the assumptions for collections growth in the second half? - Management indicated that the second quarter was driven by share gains, innovation pricing, and collections volume growth, with high single-digit growth in the U.S. and double-digit growth in Europe expected to continue [23][24] Question: Can you provide an update on IVT commercial efforts? - Management noted that hospital business was the largest contributor to margin expansion, with a focus on blood management technologies and actions to regain growth momentum in IVT [26][27] Question: How is the launch of the HN cartridge going in EMEA and Japan? - Management expects the launch to be a significant source of sustainable double-digit growth, although market dynamics differ from the U.S. [54][56] Question: What is the outlook for the Vascade business? - Management expressed confidence in regaining share in the competitive market, with ongoing initiatives to strengthen the sales force and improve market acceptance [40][45] Question: How will share repurchases impact EPS? - Management indicated that share repurchases contributed a few cents to EPS, and they aim to keep dilution in check while being opportunistic with capital deployment [39][71]

Core Insights - Haemonetics reported quarterly earnings of $1.27 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and up from $1.12 per share a year ago [1] - The earnings surprise was +13.39%, with the company having surpassed consensus EPS estimates three times in the last four quarters [2] Financial Performance - The company posted revenues of $327.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.22%, but down from $345.51 million year-over-year [3] - Haemonetics has also topped consensus revenue estimates three times over the last four quarters [3] Stock Performance and Outlook - Haemonetics shares have declined approximately 35% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [4] - The current consensus EPS estimate for the upcoming quarter is $1.28 on revenues of $330.9 million, and for the current fiscal year, it is $4.80 on revenues of $1.3 billion [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges ahead [9]